Business Context and Reporting Period
Company: Abeona Therapeutics Inc. (ABEO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2026
Reporting Period: Specific event date (March 16, 2026)
Business Context: The filing reports the Board of Directors' approval of the Third Amended and Restated Bylaws, effective March 16, 2026.
Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the adoption of new Bylaws amending the Second Amended and Restated Bylaws (dated July 9, 2024). Key amendments include:
- Meeting Procedures: Clarifications on calling, postponing, rescheduling, or canceling annual and special stockholder meetings.
- Virtual Meetings: Explicit authorization for stockholder meetings to be held virtually via remote communication.
- Stockholder Lists: Elimination of the requirement to make stockholder lists available for examination at meetings, aligning with Delaware General Corporation Law (DGCL) amendments.
- Quorum Requirement: Increase in the quorum for stockholder meetings from one-third to 50% of shares entitled to vote.
- Proposals and Nominations: Enhanced procedural mechanics and disclosure requirements for stockholder proposals and director nominations, including specific rules for utilizing "universal proxy rules."
Guidance, Outlook, and Risks
Management Commentary: The Board approved the changes to provide clarifying, ministerial, non-substantive, and conforming updates to align with current DGCL provisions and enhance procedural mechanics.
Guidance/Outlook: No financial guidance or business outlook is provided in this filing.
Risks/Contingencies: No specific risks or contingencies are disclosed in this filing beyond the standard incorporation of the full Bylaws text by reference.
Key Facts for Investor Verification
- Verify the full text of the Third Amended and Restated Bylaws filed as Exhibit 3.1 to understand the complete scope of procedural changes.
- Confirm the impact of the increased quorum requirement (50%) on the ability to conduct business at future stockholder meetings.
- Review the new disclosure requirements for stockholders proposing business or nominating directors to ensure compliance with the updated rules.
- Note that this filing references the Company's Form 10-K for the year ended December 31, 2025, for the full text of the Bylaws.